Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Equity (Deficit)

v3.19.3
Shareholders' Equity (Deficit)
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Shareholders' Equity (Deficit)

9. Shareholders’ Equity (Deficit)

The following tables present a reconciliation of our beginning and ending balances in shareholders’ equity (deficit) for the nine months ended September 30, 2019 and 2018:

 

 

 

Total

Shareholders'

Equity

 

Shareholders' equity at January 1, 2019

 

$

71,622

 

Issuance of ordinary shares

 

 

3,037

 

Exercise of share options

 

 

60

 

Share-based compensation expense

 

 

1,674

 

Net loss

 

 

(79,489

)

Shareholders' equity (deficit) at September 30, 2019

 

$

(3,096

)

 

 

 

Total

Shareholders'

Equity

 

Shareholders' equity at January 1, 2018

 

$

39,494

 

Issuance of Series B convertible preferred shares

 

 

32,159

 

Issuance of ordinary shares

 

 

74,153

 

Conversion of preferred shares to ordinary shares

 

 

74

 

Share-based compensation expense

 

 

878

 

Issuance of warrants

 

 

139

 

Net loss

 

 

(52,799

)

Shareholders' equity at September 30, 2018

 

$

94,098

 

 

On December 14, 2018, Iterum Therapeutics plc (“ITP”) and Iterum Therapeutics International Limited (“ITIL”) entered into a subscription agreement with a supplier of ITIL pursuant to which the supplier agreed to subscribe for ordinary shares in ITP in satisfaction of amounts due and owing under certain commercial agreements entered into between the supplier and ITIL (the “Subscription Agreement”). Pursuant to the terms of the Subscription Agreement, upon receipt by ITIL of a valid invoice from the supplier, ITP can elect to require the supplier to subscribe for ordinary shares in the capital of ITP (up to a maximum of 700,000 ordinary shares in total) to the value of the invoiced amount (a “Subscription”). On a Subscription, the supplier will direct ITIL to pay ITP such invoiced amount as subscription monies on the supplier’s behalf in satisfaction of the invoiced amount. 

On July 15, 2019, ITP elected that the supplier subscribe for 17,222 ordinary shares for an aggregate subscription price of $0.11 million (the “July Subscription Monies”) upon receipt by ITIL of valid invoices up to that amount from the supplier.  On that date, ITP, ITIL and the supplier executed a payment direction letter pursuant to which the parties directed ITIL to pay $0.11 million (€0.10 million) to ITP in satisfaction of the supplier’s obligation to pay the Subscription Monies to ITP and ITIL’s obligation to pay the invoiced amount to the supplier.

On August 17, 2019, ITP elected that the supplier subscribe for 245,493 ordinary shares for an aggregate subscription price of $1.67 million (the “August Subscription Monies”) upon receipt by ITIL of valid invoices up to that amount from the supplier.  On that date, ITP, ITIL and the supplier executed a payment direction letter pursuant to which the parties directed ITIL to pay $1.67 million (€1.50 million) to ITP in satisfaction of the supplier’s obligation to pay the Subscription Monies to ITP and ITIL’s obligation to pay the invoiced amount to the supplier.

On September 30, 2019, ITP elected that the supplier subscribe for 199,056 ordinary shares for an aggregate subscription price of $1.26 million (the “September Subscription Monies”) upon receipt by ITIL of valid invoices up to that amount from the supplier.  On that date, ITP, ITIL and the supplier executed a payment direction letter pursuant to which the parties directed ITIL to pay $1.26 million (€1.15 million) to ITP in satisfaction of the supplier’s obligation to pay the Subscription Monies to ITP and ITIL’s obligation to pay the invoiced amount to the supplier.